ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 600,37
0,38%
Dow Jones
38 778,10
0,00%
DAX
18 103,49
0,16%
Brent Oil
83,765
-0,16%
Bitcoin
65 300,72
-1,78%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Alterity Therapeutics Limited (ATHE)

  7. Alterity Therapeutics Limited (ATHE) Actualités

ATHE

Alterity Therapeutics (ATHE)

Alterity Therapeutics Limited
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ATHE
DateHeureSourceTitreSymboleSociété
13/06/202414h28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
13/06/202401h22GlobeNewswire Inc.Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ WebinarNASDAQ:ATHEAlterity Therapeutics Limited
30/05/202401h21GlobeNewswire Inc.Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History StudyNASDAQ:ATHEAlterity Therapeutics Limited
08/05/202413h25GlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewNASDAQ:ATHEAlterity Therapeutics Limited
30/04/202413h25GlobeNewswire Inc.Appendix 4C – Q3 FY24 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
29/04/202413h25GlobeNewswire Inc.Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s AtaxiaNASDAQ:ATHEAlterity Therapeutics Limited
17/04/202413h25GlobeNewswire Inc.Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
10/04/202413h25GlobeNewswire Inc.Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024NASDAQ:ATHEAlterity Therapeutics Limited
26/03/202415h25GlobeNewswire Inc.Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundNASDAQ:ATHEAlterity Therapeutics Limited
20/02/202416h25GlobeNewswire Inc.Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
15/02/202423h28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATHEAlterity Therapeutics Limited
06/02/202413h25GlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second ReviewNASDAQ:ATHEAlterity Therapeutics Limited
29/01/202413h24GlobeNewswire Inc.Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekNASDAQ:ATHEAlterity Therapeutics Limited
22/01/202413h25GlobeNewswire Inc.Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesNASDAQ:ATHEAlterity Therapeutics Limited
21/12/202306h30GlobeNewswire Inc.Alterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerNASDAQ:ATHEAlterity Therapeutics Limited
04/12/202322h35GlobeNewswire Inc.Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical ProgressNASDAQ:ATHEAlterity Therapeutics Limited
04/12/202313h25GlobeNewswire Inc.Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s DiseaseNASDAQ:ATHEAlterity Therapeutics Limited
27/11/202313h25GlobeNewswire Inc.Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System AtrophyNASDAQ:ATHEAlterity Therapeutics Limited
16/11/202313h25GlobeNewswire Inc.Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434NASDAQ:ATHEAlterity Therapeutics Limited
08/11/202313h25GlobeNewswire Inc.Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System AtrophyNASDAQ:ATHEAlterity Therapeutics Limited
30/10/202312h25GlobeNewswire Inc.Appendix 4C – Q1 FY24 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
26/10/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATHEAlterity Therapeutics Limited
31/08/202313h25GlobeNewswire Inc.Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian DisorderNASDAQ:ATHEAlterity Therapeutics Limited
23/08/202313h25GlobeNewswire Inc.Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’sNASDAQ:ATHEAlterity Therapeutics Limited
22/08/202313h25GlobeNewswire Inc.Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement DisordersNASDAQ:ATHEAlterity Therapeutics Limited
15/08/202313h25GlobeNewswire Inc.Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive RefundNASDAQ:ATHEAlterity Therapeutics Limited
31/07/202313h52GlobeNewswire Inc.Appendix 4C – Q4 FY23 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
26/07/202313h25GlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as PlannedNASDAQ:ATHEAlterity Therapeutics Limited
21/06/202313h25GlobeNewswire Inc.Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023NASDAQ:ATHEAlterity Therapeutics Limited
21/06/202312h09Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ATHEAlterity Therapeutics Limited
 Showing the most relevant articles for your search:NASDAQ:ATHE

Dernières Valeurs Consultées

LSE
0GO6
Studsvik Ab
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés